TABLE 6.
Percent susceptible for cefiderocol, ceftazidime-avibactam, eravacycline, and comparator agents by region among 343 carbapenem-resistant Escherichia coli clinical isolates
| Agentb,c | No. of isolates (%)a |
Pd | ||||
|---|---|---|---|---|---|---|
| Total (n = 343) | North America (n = 203) | Asia-West Pacific (n = 59) | Europe (n = 64) | Latin America (n = 17) | ||
| CFDC | 315 (92) | 189 (93) | 53 (90) | 57 (89) | 16 (94) | |
| CZA | 281 (82) | 186 (92) | 30 (51) | 50 (78) | 15 (88) | <0.001 |
| ERV | 335 98) | 197 (97) | 58 (98) | 64 (100) | 16 (94) | |
| MEM | 203 (60) | 153 (75) | 7 (12) | 35 (55) | 8 (47) | <0.001 |
| IPM | 100 (29) | 90 (44) | 4 (7) | 3 (5) | 3 (18) | <0.001 |
| ETP | 15 (4) | 7 (3) | 2 (4) | 5 (8) | 1 (6) | |
| GEN | 189 (56) | 131 (65) | 18 (31) | 32 (50) | 8 (47) | <0.001 |
| TZP | 72 (21) | 56 (28) | 10 (17) | 3 (5) | 3 (18) | 0.001 |
| AMK | 269 (78) | 166 (82) | 40 (68) | 50 (78) | 13 (77) | <0.001 |
| LVX | 62 (18) | 40 (20) | 1 (1.7) | 18 (28) | 3 (18) | 0.001 |
| TGC | 340 (99) | 200 (99) | 59 (100) | 64 (100) | 17 (100) | |
| CAZ | 36 (1) | 19 (9) | 0 (0) | 16 (25) | 1 (6) | <0.001 |
| MIN | 231 (67) | 141 (70) | 35 (59) | 45 (70) | 10 (59) | |
a
Values for each agent are expressed as no. of isolates (column %).
b
Abbreviations: AMK, amikacin; CFDC, cefiderocol; CAZ, ceftazidime; CZA, ceftazidime-avibactam; ERV, eravacycline; ETP, ertapenem; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; MIN, minocycline; TZP, piperacillin-tazobactam; TGC, tigecycline.
c
CL, colistin: not shown; all isolates resistant.
d
P values, as determined by chi-square test, for overall four-group comparisons are shown where P < 0.05.